HomeCompareAVEO vs BTI

AVEO vs BTI: Dividend Comparison 2026

AVEO yields 13.33% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVEO wins by $10.4K in total portfolio value
10 years
AVEO
AVEO
● Live price
13.33%
Share price
$15.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.1K
Annual income
$3,052.37
Full AVEO calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — AVEO vs BTI

📍 AVEO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVEOBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVEO + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVEO pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVEO
Annual income on $10K today (after 15% tax)
$1,133.33/yr
After 10yr DRIP, annual income (after tax)
$2,594.51/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, AVEO beats the other by $225.87/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVEO + BTI for your $10,000?

AVEO: 50%BTI: 50%
100% BTI50/50100% AVEO
Portfolio after 10yr
$42.9K
Annual income
$2,919.50/yr
Blended yield
6.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

AVEO
Analyst Ratings
5
Buy
14
Hold
1
Sell
Consensus: Hold
Price Target
$14.00
-6.7% upside vs current
Range: $14.00 — $14.00
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVEO buys
0
BTI buys
0
No recent congressional trades found for AVEO or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVEOBTI
Forward yield13.33%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$48.1K$37.7K
Annual income after 10y$3,052.37$2,786.64
Total dividends collected$21.6K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$14.00$40.00

Year-by-year: AVEO vs BTI ($10,000, DRIP)

YearAVEO PortfolioAVEO Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$12,033$1,333.33$11,299$598.92+$734.00AVEO
2$14,375$1,499.48$12,794$703.91+$1.6KAVEO
3$17,056$1,674.11$14,518$829.07+$2.5KAVEO
4$20,106$1,856.32$16,513$978.64+$3.6KAVEO
5$23,558$2,045.14$18,827$1,157.84+$4.7KAVEO
6$27,447$2,239.56$21,518$1,373.12+$5.9KAVEO
7$31,807$2,438.54$24,657$1,632.46+$7.2KAVEO
8$36,674$2,641.02$28,329$1,945.74+$8.3KAVEO
9$42,087$2,845.96$32,637$2,325.33+$9.4KAVEO
10$48,086$3,052.37$37,708$2,786.64+$10.4KAVEO

AVEO vs BTI: Complete Analysis 2026

AVEOStock

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Full AVEO Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this AVEO vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVEO vs SCHDAVEO vs JEPIAVEO vs OAVEO vs KOAVEO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.